Copy Link Print Information

Lenvatinib mesylate

(Synonyms: E7080 mesylate; MK-7902 mesylate)
105 Cited Publications
Avis client

Based on 105 publication(s) in Google Scholar

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

  • Pureté : 99.91%
  • CAS No.: 857890-39-2
  • Formule: C22H23ClN4O7S
  • Masse moléculaire:522.96
  • Stockage:

    4°C, sealed storage, away from moisture and light

    * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

  • Lenvatinib mesylate Chemical Structure
    Lenvatinib mesylate Chemical Structure
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
  • Experimental Validation Results for Lenvatinib mesylate
CAS No.: 857890-39-2
Size
Prix
Stock
Quantité
Amount: USD 0.00
Please select quantity
or
or

* Veuillez sélectionner la quantité avant d'ajouter des articles.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Lenvatinib mesylate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Trouvez votre distributeur local Your local distributor: Hycultec GmbHHycultec
  • Activité biologique
  • Chemical Information
  • Solvant et solubilité
  • Pureté et documentation
  • Références
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Lenvatinib mesylate

More
Customer Validation & Images
IHCCell Proliferation/Viability AssayRT-PCRWB
  • IHC
  • Cell Proliferation/Viability Assay
  • WB
  • Cell Proliferation/Viability Assay
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • WB

Voir tous les produits spécifiques à Isoform VEGFR

More

Voir tous les produits spécifiques à Isoform PDGFR

More

Keywords

MOQ
Minimum order quantity
100 mg

Obtenir un devis En stock

Other size
Obtenir un devis
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Sign In
Enregistrer
Sign in to MedChemExpress
Enregistrer un nouveau compte

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Lenvatinib mesylate Chemical Structure
    Lenvatinib mesylate Chemical Structure
    1/16
  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Transl Med. 2022 Mar 7;20(1):116. [Abstract]

    Customer Validation
     H&E examination of vehicle and Lenvatinib (10 mg/kg daily by oral gavage)-treated tumors revealed markedly increase tumor necrosis and desmoplasia in the Lenvatinib-treated samples.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Oncol. 2022 Oct 18;2022:4537343. [Abstract]

    Customer Validation
     HepG2 and HepG2/R cells are treated with indicated doses of Lenvatinib for 24 h, and cellular viabilities are measured.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Oncol. 2022 Oct 18;2022:4537343. [Abstract]

    Customer Validation
     HepG2 and HepG2/R cells are treated with or without Lenvatinib (20 μM) for 24 h, and indicated proteins are measured by western blots.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: Cell Death Discov. 2021 Nov 18;7(1):359. [Abstract]

    Customer Validation
     Lenvatinib (1000 nM) has demonstrated the ability to significantly inhibit cell proliferation, and knockout of NF1 and DUSP9 significantly blocks the ability of lenvatinib to inhibit cell proliferation as well as the effect on cell number. ​

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]

    Customer Validation
     The cell viability is measured by CCK-8 assay at different time intervals (24, 48, 72 and 96 h) when cells are cultured with 5 μM Lenvatinib.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]

    Customer Validation
     The mRNA expression of VEGFR2 in HepG2-WT/Lenvatinib (LR; 5 μM) and Huh7-WT/LR cells. VEGFR2 mRNA expression is up-regulated in HepG2-LR and Huh7LR cells.

  • 1/16

    Lenvatinib mesylate purchased from MedChemExpress. Usage Cited in: J Cell Mol Med. 2021 Jan;25(1):549-560. [Abstract]

    Customer Validation
     The protein expression of VEGFR2 in HepG2-WT/Lenvatinib (LR; 5 μM) and Huh7-WT/LR cells. Western blotting results show the downstream target RAS/MEK/ERK axis of VEGFR2 are obviously up‐regulated in HepG2-LR and Huh7-LR cells compared with their parental cells.

  • Lenvatinib mesylate